SEC Comment Letter for BioPharmX Corp (CIK 0001504167) — May 7, 2021

BioPharmX Corp (CIK 0001504167)
Date: May 7, 2021 · CIK: 0001504167 · Accession: 0000000000-21-005885

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-255743

Date

May 7, 2021

Author

Division of Corporation Finance

Form

UPLOAD

Company

BioPharmX Corp (CIK 0001504167)

Letter

United States securities and exchange commission logo May 7, 2021 John Koconis Chief Executive Officer and Chairman of the Board of Directors Timber Pharmaceuticals, Inc. 110 Allen Road, Suite 401 Basking Ridge, NJ 07920

Re: Timber Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 4, 2021 File No. 333-255743

Dear Mr. Koconis:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Margaret Schwartz at 202-551-7153 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                          May 7, 2021

       John Koconis
       Chief Executive Officer and Chairman of the Board of Directors
       Timber Pharmaceuticals, Inc.
       110 Allen Road, Suite 401
       Basking Ridge, NJ 07920

                                                        Re: Timber
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed May 4, 2021
                                                            File No. 333-255743

       Dear Mr. Koconis:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Margaret
Schwartz at 202-551-7153 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Alan Wovsaniker, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io